Timing use of novel anti-epileptic drugs: is earlier better?

References

• Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88:296–303.
   PubMed Web of Science ®Google Scholar
• Younus I, Reddy DS. A resurging boom in new drugs for epilepsy and brain disorders. Expert Rev Clin Pharmacol. 2018;11:27–45.
   PubMed Web of Science ®Google Scholar
• Zeng QY, Fan TT, Zhu P, et al. Comparative long-term effectiveness of a monotherapy with five antiepileptic drugs for focal epilepsy in adult patients: a prospective cohort study. PLoS One. 2015;10:e0131566.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Medical management of refractory epilepsy - practical treatment with novel antiepileptic drugs. Epilepsia. 2014;55(Suppl 1):3–8.
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Brodie MJ. Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults. Curr Opin Neurol. 2012;25:164–172.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548–1554.
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000–1015.
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)-part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52:927–966.
   PubMed Web of Science ®Google Scholar
• Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9:68–82.
   PubMed Web of Science ®Google Scholar
• Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet. 2015;54:901–914.
   PubMed Web of Science ®Google Scholar
• de Biase S, Valente M, Gigli GL, et al. Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures. Expert Opin Drug Metab Toxicol. 2017;13:997–1005.
   PubMed Web of Science ®Google Scholar
• UCB Pharma. Vimpat® (lacosamide). Prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022253s042lbl.pdf [Last accessed 2019 Apr 25]
   Google Scholar
• Franquiz MJ, Kalaria SN, Armahizer MJ, et al. Lacosamide pharmacokinetics in a critically ill patient receiving continuous venovenous hemofiltration. Pharmacother J Hum Pharmacol Drug Ther. 2017;38:e17–21.
   Google Scholar
• LaPenna P, Tormoehlen LM. The pharmacology and toxicology of third-generation anticonvulsant drugs. J Med Toxicol. 2017;13:329–342.
   PubMed Web of Science ®Google Scholar
• UCB Pharma. Vimpat® (lacosamide): EMA summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/vimpat-epar-product-information_en.pdf [Last accessed 2019 Apr 25]
   Google Scholar
• Contin M, Albani F, Riva R, et al. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013;35:849–852.
   PubMed Web of Science ®Google Scholar
• Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:443–453.
   PubMed Web of Science ®Google Scholar
• Galgani A, Palleria C, Iannone LF, et al. Pharmacokinetic Interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Front Neurol. 2018;9.
   PubMed Web of Science ®Google Scholar
• Hebeisen S, Pires N, Loureiro AI, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 2015;89:122–135.
   PubMed Web of Science ®Google Scholar
• Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate: pharmacokinetics and drug interactions of ESL. Epilepsia. 2012;53:935–946.
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40:526–548.
   PubMed Web of Science ®Google Scholar
• Bial. Zebinix® (eslicarbazepine). Product information. Available at: https://www.ema.europa.eu/en/documents/product-information/zebinix-epar-product-information_en.pdf [Last accessed 2019 Apr 25]
   Google Scholar
• Almeida L, Falcão A, Maia J, et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol. 2005;45:1062–1066.
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Antiepileptic drug interactions: a clinical guide. New York, NY: Springer Berlin Heidelberg; 2016.
   Google Scholar
• Eisai. Fycompa® (perampanel): EMA summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf. [Last accessed 2019 Apr 25]
   Google Scholar
• Yamamoto Y, Takahashi Y, Horino A, et al. Influence of inflammation on the pharmacokinetics of perampanel. Ther Drug Monit. 2018;40:725–729.
   PubMed Web of Science ®Google Scholar
• Eisai. Fycompa® (perampanel). Prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf [Last accessed 2019 Apr 25]
   Google Scholar
• Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56:12–27.
   PubMed Web of Science ®Google Scholar
• Majid O, Laurenza A, Ferry J, et al. Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials: impact of perampanel on clearance of concomitant AEDs. Br J Clin Pharmacol. 2016;82:422–430.
   PubMed Web of Science ®Google Scholar
• Klein P, Diaz A, Gasalla T, et al. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol Adv Appl. 2018;10:1–22.
   PubMed Web of Science ®Google Scholar
• Baltes S, Gastens AM, Fedrowitz M, et al. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007;52:333–346.
   PubMed Web of Science ®Google Scholar
• UCB Pharma. Briviact® (brivaracetam): EMA summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/briviact-epar-product-information_en.pdf [Last accessed 2019 Apr 25]
   Google Scholar
• UCB Pharma. Briviact® (brivaracetam). Prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205836s005,205837s004,205838s003lbl.pdf [Last accessed 2019 Apr 25]
   Google Scholar
• Stockis A, Chanteux H, Rosa M, et al. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. 2015;113:19–27.
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–1393.
   PubMed Web of Science ®Google Scholar
• Fishman J, Kalilani L, Song Y, et al. Antiepileptic drug titration and related health care resource use and costs. J Manag Care Spec Pharm. 2018;24:929–938.
   PubMed Web of Science ®Google Scholar
• Asconapé JJ. Pharmacokinetic considerations with the use of antiepileptic drugs in patients with HIV and organ transplants. Curr Neurol Neurosci Rep. 2018;18:89.
   PubMed Web of Science ®Google Scholar
• Birbeck GL, French JA, Perucca E, et al. Evidence-based guideline: antiepileptic drug selection for people with HIV/AIDS: report of the quality standards subcommittee of the American academy of neurology and the Ad hoc task force of the commission on therapeutic strategies of the international league against epilepsy. Neurology. 2012;78:139–145.
   PubMed Web of Science ®Google Scholar
• Barrachina-Martínez I, Vivas-Consuelo D, Piera-Balbastre A. Budget impact analysis of brivaracetam adjunctive therapy for partial-onset epileptic seizures in valencia community, Spain. Clin Drug Investig. 2017;38:353–363.
   Web of Science ®Google Scholar
• Simoens S, De Naeyer L, Dedeken P. Cost Effectiveness of Lacosamide in the Adjunctive Treatment of Patients with Refractory Focal Epilepsy in Belgium. CNS Drugs. 2012;26:337–350.
   PubMed Web of Science ®Google Scholar
• Geitona M, Kousoulakou H, Carayianni V, et al. Economic evaluation of lacosamide in the management of epileptic partial onset seizures in Greece. Value Health. 2014;17:397–398.
   PubMed Web of Science ®Google Scholar
• Sánchez Fernández I, Gaínza-Lein M, Lamb N, et al. Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus. Neurology. 2019;92:e2339–48.
   PubMed Web of Science ®Google Scholar
• Tremblay G, Howard D, Tsong W, et al. Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspective. Epilepsy Behav. 2018;86:108–115.
   PubMed Web of Science ®Google Scholar
• Borghs S, Thieffry S, Noack-Rink M, et al. Health care cost associated with the use of enzyme-inducing and non-enzyme–active antiepileptic drugs in the UK: a long-term retrospective matched cohort study. BMC Neurol. 2017;17:59.
   PubMed Web of Science ®Google Scholar
• de Kinderen RJA, Evers SM, Rinkens R, et al. Side-effects of antiepileptic drugs: the economic burden. Seizure. 2014;23:184–190.
   PubMed Web of Science ®Google Scholar
• Zhu L, Chen D, Xu D, et al. Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: an indirect comparison. Seizure. 2017;51:121–132.
   PubMed Web of Science ®Google Scholar
• Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomized, double-blind, non-inferiority trial. Lancet Neurol. 2017;16:43–54.
   PubMed Web of Science ®Google Scholar
• Baulac M, Byrnes W, Williams P, et al. Lacosamide and sodium channel-blocking antiepileptic drug a cross-titration against levetiracetam background therapy. Acta Neurol Scand. 2017;135:434–441.
   PubMed Web of Science ®Google Scholar
• Kwon SJ, Barletta JF, Hall ST, et al. Lacosamide versus phenytoin for the prevention of early post-traumatic seizures. J Crit Care. 2018;50:50–53.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Zollner JP, Willems LM, et al. Lacosamide in status epilepticus: systematic review of current evidence. Epilepsia. 2017;58:933–950.
   PubMed Web of Science ®Google Scholar
• Misra UK, Dubey D, Kalita J. Comparison of lacosamide versus sodium valproate in status epilepticus: a pilot study. Epilepsy Behav. 2017;76:110–113.
   PubMed Web of Science ®Google Scholar
• Brigo F, Trinka E. Randomized controlled trials in status epilepticus: size matters. Epilepsia. 2017;58:915.
   PubMed Web of Science ®Google Scholar
• Makinen J, Rainesalo S, Peltola J. Transition from oxcarbazepine to eslicarbazepine acetate: a single center study. Brain Behav. 2017;7:e00634.
   PubMed Web of Science ®Google Scholar
• Pazdera L, Sperling MR, Harvey JH, et al. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine. Epilepsia. 2018;59:704–714.
   PubMed Web of Science ®Google Scholar
• Trinka E, Ben-Menachem E, Kowacs PA, et al. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: a phase III double-blind, randomized, parallel-group, multicenter study. Epilepsia. 2018;59:479–491.
   PubMed Web of Science ®Google Scholar
• Villanueva V, Montoya J, Castillo A, et al. Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study. Epilepsia. 2018;59:1740–1752.
   PubMed Web of Science ®Google Scholar
• Goldsmith D, Minassian BA. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav. 2016;62:132–135.
   PubMed Web of Science ®Google Scholar
• Crespel A, Gelisse P, Tang NP, et al. Perampanel in 12 patients with Unverricht-Lundborg disease. Epilepsia. 2017;58:543–547.
   PubMed Web of Science ®Google Scholar
• Maschio M, Pauletto G, Zarabia A, et al. Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis. Int J Neurosci. 2018;3:1–10.
   Google Scholar
• Zhang L, Li S, Li H, et al. Levetiracetam vs. brivaracetam for adults with refractory focal seizures: A meta-analysis and indirect comparison. Seizure. 2016;39:28–33.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia. 2018;59:1549–1556.
   PubMed Web of Science ®Google Scholar
• Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57:201–209.
   PubMed Web of Science ®Google Scholar
• Kalss G, Roharacher A, Leitinger M, et al. Intravenous brivaracetam in status epilepticus: a retrospective single center study. Epilepsia. 2018;59:228–233.
   PubMed Web of Science ®Google Scholar
• Li-Na Z, Deng C, Hai-Jiao W, et al. Indirect comparison of third-generation antiepileptic drugs as adjunctive treatment for uncontrolled focal epilepsy. Epilepsy Res. 2018;139:60–72.
   PubMed Web of Science ®Google Scholar
• Brigo F, Bragazzi NL, Nardone R, et al. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: results of an indirect comparison meta-analysis of RCTs. Seizure. 2016;42:29–37.
   PubMed Web of Science ®Google Scholar
• Khan N, Shah D, Tongbram V, et al. The efficacy and tolerability of perampanel and other recently approved anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis. Curr Med Res Opin. 2013;29:1001–1013.
   PubMed Web of Science ®Google Scholar
• Brigo F, Trinka E, Bragazzi NL, et al. A common reference-based indirect comparison meta-analysis of eslicarbazepine versus lacosamide as add on treatments for focal epilepsy. Epilepsy Res. 2016;127:12–18.
   PubMed Web of Science ®Google Scholar
• Bassel AK, Schmidt D. Antiepileptic drugs: advantages and disadvantages. Nashville (TN): Elsevier; 2012.
   Google Scholar
• French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2:141–158.
   PubMedGoogle Scholar
• Delaunois AC, Colomar A, Depelchin B, et al. Cardiac safety of lacosamide: the non-clinical perspective. Acta Neurol Scan. 2015;132:337–345.
   PubMed Web of Science ®Google Scholar
• Rudd GD, Haverkamp W, Mason JW, et al. Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures. Acta Neurol Scand. 2015;132:355–363.
   PubMed Web of Science ®Google Scholar
• Newey CR, Le NM, Ahrens C, et al. The safety and effectiveness of intravenous Lacosamide for refractory status epilepticus in the critically ill. Neurocrit Care. 2016;26:273–279.
   Web of Science ®Google Scholar
• Kellinghaus C, Berning S, Stögbauer F. Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. Acta Neurol Scand. 2014;129:294–299.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovannelli F, Maratea D, et al. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure. 2013;22:528–536.
   PubMed Web of Science ®Google Scholar
• Gama H, Vieira M, Costa R, et al. Safety profile of eslicarbazepine acetate as add-on therapy in adults with refractory focal-onset seizures: from clinical studies to 6 years of post-marketing experience. Drug Saf. 2017;40:1231–1240.
   PubMed Web of Science ®Google Scholar
• Villanueva V, Serratosa JM, Guillamòn E, et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res. 2014;108:1243–1252.
   PubMed Web of Science ®Google Scholar
• Jalihal V, Shankar R, Henley W, et al. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events. Epilepsy Behav. 2018;80:365–369.
   PubMed Web of Science ®Google Scholar
• de Biase S, Gigli GL, Nilo A, et al. Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures. Expert Opin Drug Metab Toxicol. 2019;15:93–102.
   PubMed Web of Science ®Google Scholar
• Liguori C, Izzi F, Manfredi N, et al. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: a retrospective single center study. Epilepsy Behav. 2018;80:173–176.
   PubMed Web of Science ®Google Scholar
• Chung S, Williams B, Dobrinsky C, et al. Perampanel with concomitant levetiracetam and topiramate: post hoc analysis of adverse events related to hostility and aggression. Epilepsy Behav. 2017;75:79–85.
   PubMed Web of Science ®Google Scholar
• Pina-Garza JE, Lagae L, Villanueva V, et al. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. Epilepsy Behav. 2018;83:50–58.
   PubMed Web of Science ®Google Scholar
• Coppola G, Iapadre G, Operto FF, et al. New developments in the management of partial-onset epilepsy: role of brivaracetam. Drug Des Dev Ther. 2017;11:643–657.
   PubMed Web of Science ®Google Scholar
• Makke Y, Abou-Khalil B. Brivaracetam efficacy and safety in focal epilepsy. Expert Rev Neurother. 2019. Epub ahead of print. DOI:10.1080/14737175.2019.1631160
   PubMed Web of Science ®Google Scholar
• Hirsch M, Hintz M, Specht A, et al. Tolerability, efficacy and retention rate of BRV in patients previously treated with LEV: a monocenter retrospective outcome analysis. Seizure. 2018;61:98–103.
   PubMed Web of Science ®Google Scholar
• Yates SL, Fakhoury T, Liang W, et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52:165–168.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovannelli F, Giorgi FS, et al. Tolerability of new antiepileptic drug: a network meta-analysis. Eur J Pharmacol. 2017;73:811–817.
   Web of Science ®Google Scholar
• Klein P, Biton V, Dilley D, et al. Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy. Epilepsia. 2016;57:1130–1138.
   PubMed Web of Science ®Google Scholar
• Schulze-Bonhage A. Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation. Expert Opin Drug Metab Toxicol. 2015;11:1329–1337.
   PubMed Web of Science ®Google Scholar
• Costa J, Fareleira F, Ascenção R, et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia. 2011;52:1280–1291.
   PubMed Web of Science ®Google Scholar
• Fountain NB, Krauss G, Isojarvi J, et al. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamidenaive patients with partial-onset seizures. Epilepsia. 2013;54:58–65.
   PubMed Web of Science ®Google Scholar
• Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009;61:197–216.
   PubMed Web of Science ®Google Scholar
• Rudzinski LA, Vélez-Ruiz NJ, Gedzelman ER, et al. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel. J Investig Med. 2016;64:1087–1101.
   PubMed Web of Science ®Google Scholar
• Moshé SL, Perucca E, Ryvlin P, et al. Epilepsy: new advances. Lancet. 2015;385:884–898.
   PubMed Web of Science ®Google Scholar